SCHEDULE: Viking Global Amends BridgeBio Pharma Stake
Schedule 13D Amendment
Viking Global Investors LP and affiliates updated their beneficial ownership in BridgeBio Pharma, Inc., reporting a net reduction in shares since July 1, 2025.
Summary
- Viking Global Investors LP and its affiliated entities, including Viking Global Performance LLC, Viking Global Equities II LP, Viking Global Equities Master Ltd., Viking Long Fund GP LLC, Viking Long Fund Master Ltd., Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, and Viking Global Opportunities Liquid Portfolio Sub-Master LP, along with individuals O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet, filed an Amendment No. 8 to their Schedule 13D.
- The reporting persons collectively beneficially own 18,602,920 shares of BridgeBio Pharma, Inc. Common Stock, representing 9.7% of the outstanding shares.
- This percentage is calculated based on 191,168,504 shares of Common Stock outstanding as of July 29, 2025, as reported in BridgeBio Pharma's Form 10-Q filed on August 5, 2025.
- Since the filing of Amendment No. 7 on July 1, 2025, the reporting persons engaged in a series of open market transactions.
- Total purchases amounted to 9,368 shares, with prices ranging from $45.0712 to $45.7165 per share.
- Total sales amounted to 832,105 shares, with prices ranging from $47.007 to $47.6756 per share.
- The net effect of these transactions is a reduction of 822,737 shares in the reporting persons' aggregate holdings.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership changes and transactions. While the net selling activity by the reporting group could be interpreted as a slightly negative signal from their perspective, the document itself is neutral and standard for a Schedule 13D amendment.
Negatives
- The reporting persons engaged in net selling activity, reducing their aggregate beneficial ownership by 822,737 shares since July 1, 2025.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of changes in beneficial ownership by a significant institutional investor in a biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape beyond the investor's positioning within the sector.
Stakeholder Impact
- Shareholders: Changes in significant institutional ownership can influence market perception and potentially stock price. The net selling activity by Viking Global may be viewed by other investors as a signal regarding the stock's prospects.
Key Dates
| Date | Description |
|---|---|
| 2019-07-08 | Original Schedule 13D filed with the Commission. |
| 2023-07-19 | Amendment No. 1 to Schedule 13D filed. |
| 2023-11-22 | Amendment No. 2 to Schedule 13D filed. |
| 2024-08-20 | Amendment No. 3 to Schedule 13D filed. |
| 2024-11-06 | Amendment No. 4 to Schedule 13D filed. |
| 2025-01-31 | Amendment No. 5 to Schedule 13D filed. |
| 2025-03-12 | Amendment No. 6 to Schedule 13D filed. |
| 2025-07-01 | Amendment No. 7 to Schedule 13D filed, marking the start of the transaction period reported in this amendment. |
| 2025-07-09 | First reported purchase transaction by VLFM. |
| 2025-07-15 | First reported sale transactions by multiple reporting persons. |
| 2025-07-29 | Date as of which BridgeBio Pharma, Inc. reported 191,168,504 shares outstanding in its Form 10-Q. |
| 2025-08-04 | Last reported sale transactions by multiple reporting persons. |
| 2025-08-05 | BridgeBio Pharma, Inc.'s quarterly report on Form 10-Q filed with the SEC. |
| 2025-08-14 | Date of event which requires filing of this Amendment No. 8 to Schedule 13D. |
Keywords
BridgeBio Pharma, Viking Global Investors, Schedule 13D, Beneficial Ownership, Common Stock, Institutional Investor, Shareholding, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.